Immediate surgery can improve outcomes among women age 70 and older who are not receiving radiotherapy, data suggest.

This page includes links to articles highlighting the top skin cancer research published on Cancer Therapy Advisor in 2024.

Pembrolizumab plus fulvestrant provided disease control in 50% of patients with ER-positive, HER2-negative metastatic breast cancer.

PM8002/BNT327 plus nab-paclitaxel demonstrated “clinically meaningful” activity in advanced TNBC, according to researchers.

Researchers say they have identified several factors that may be associated with inadequate ovarian function suppression.

Fedratinib can reduce symptoms and spleen volume in patients with myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPNs), according to research presented at the ASH Annual Meeting 2024.

Lenalidomide improved upon the efficacy of durvalumab in patients with refractory or advanced CTCL in a phase 1/2 trial.

Teclistamab maintenance, given alone or in combination with lenalidomide, demonstrated “unprecedented efficacy” in multiple myeloma patients.

Blinatumomab plus chemotherapy represents a new standard of care for most children with NCI standard-risk B-cell ALL, according to Rachel E. Rau, MD.

Rucaparib Maintenance Improves Long-Term Outcomes in Ovarian Cancer Rucaparib maintenance after first-line chemotherapy and ...

Ibrutinib-containing regimens may be the “preferred” first-line treatment for MCL, and most patients may be able to forgo ASCT, study results suggest.

IFRT did not provide a long-term survival benefit in patients with stage IA-IIA Hodgkin lymphoma who were PET-negative after first-line chemotherapy.